Researchers feel that combining navitoclax with ruxolitinib should help those with myelofibrosis. In this particular trial half the individuals have navitoclax and ruxolitinib. The opposite half have ruxolitinib along with a dummy drug (placebo ). This trial was sponsored by Abbott Laboratories and Genentech. M06-814 was the main in human https://galileom777bnd0.hamachiwiki.com/user